A vast stock of a typhoid vaccine, intended to immunize travelers against typhoid fever, has been recalled by the pharmaceutical company who manufactured it. The reason for the recall was that the vaccine simply did not work.
The typhoid vaccine was manufactured by the 'big pharma' company, the French firm Sanofi Pasteur. The vaccine goes under the trade name of Typhim Vi.
According to the BBC, the vaccine was recalled due to 88% of the batch having insufficient potency. This means that either the vaccine will not work or that it will not work very effectively and that anyone immunized could have received the weaker vaccine.
Typhoid fever is a disease where those infected experience sustained temperatures of 103 degrees Fahrenheit or higher, as well as stomach pains and rose-colored spots. It is caused by the bacterium Salmonella Typhi.
The disease is not common in the U.S. or Europe, but it still causes 21 million infections per year in several regions of the world, such as South or South East Asia. It is a requirement for most tourists to countries with incidences of typhoid to receive a vaccine shot before traveling.
In a press release, Ian Holloway, Head of Defective Medicines Report Center of the European Medicines Agency, said: "There are no concerns over the safety of this vaccine, but the recall has taken place because the vaccine may not be as effective as it should be."
The forecastle is likely to cost Sanofi Pasteur several million dollars.